Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01816841 · ClinicalTrials.gov registry record · NA
Direct Visual Fluorescence in Finding Oral Cancer in High-Risk Patients and Patients Undergoing Routine Dental Care
A NA study of Tongue Cancer and Stage 0 Lip and Oral Cavity Cancer, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 68
- Enrollment target
- 1
- Study location
NCT01816841: Completed NA study of Tongue Cancer and Stage 0 Lip and Oral Cavity Cancer, sponsored by Ohio State University Comprehensive Cancer Center.
NCT01816841 is a NA study of Tongue Cancer and Stage 0 Lip and Oral Cavity Cancer that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 68 participants, below the 100-participant average among 3 other Tongue Cancer trials with a reported enrollment target (32% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01816841, a NA study of Tongue Cancer and Stage 0 Lip and Oral Cavity Cancer, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 68 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial studies direct visual fluorescence in finding oral cancer in high-risk patients and patients undergoing routine dental care. Diagnostic procedures, such as direct visual fluorescence, may help find and diagnose oral cancer.
Primary Outcome
Will be evaluated by calculating sensitivity and specificity and their corresponding exact 95% confidence intervals. Association between the two techniques will be assessed using the simple kappa statistic.
Conditions Studied
Interventions
- PROCEDURE biopsy
- PROCEDURE fluorescence imaging
- PROCEDURE examination
- PROCEDURE Comparison of surgical margins by COE vs. DVFE
Study Locations (1)
Ohio
- Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2008-11-11 |
| Est. Completion | 2019-12-28 |
| Phase | NA |
What the finished NCT01816841 record still lists
NCT01816841 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, below the 100-participant average among 3 other Tongue Cancer trials with a reported enrollment target (32% lower).
The record links to 4 conditions, with Tongue Cancer appearing as the primary indexed condition, and to 4 interventions - of which biopsy is the first listed.
NCT01816841 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT01816841 about?
NCT01816841 is a clinical study titled "Direct Visual Fluorescence in Finding Oral Cancer in High-Risk Patients and Patients Undergoing Routine Dental Care". This clinical trial studies direct visual fluorescence in finding oral cancer in high-risk patients and patients undergoing routine dental care. Diagnostic procedures, such as direct visual fluorescence, may help find and diagnose oral cancer.
What is the current status of trial NCT01816841?
This trial is currently completed. It is a NA study. The enrollment target is 68 participants. The study started on 2008-11-11. Estimated completion is 2019-12-28.
What conditions does trial NCT01816841 study?
This clinical trial studies the following conditions: Tongue Cancer, Stage 0 Lip and Oral Cavity Cancer, Lip and Oral Cavity Squamous Cell Carcinoma, Oral Cavity Verrucous Carcinoma.
What interventions are being tested in trial NCT01816841?
The interventions under investigation include: biopsy (PROCEDURE), fluorescence imaging (PROCEDURE), examination (PROCEDURE), Comparison of surgical margins by COE vs. DVFE (PROCEDURE).
Who is sponsoring clinical trial NCT01816841?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01816841 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tongue Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Surgeon-performed Ultrasound for Real-time Guidance In Oral Cancer Surgeries - A Multicenter Randomized Controlled Trial
RECRUITING · NA
-
Prosthesis Guided Speech Rehabilitation of T1/T2 Cancers of the Tongue
RECRUITING · NA
-
A Study of Tongue Strength and Endurance Using the Iowa Oral Performance Instrument (IOPI) Tongue Strength Trainer in People With Oral Tongue Cance
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI